Christophe Thurieau joins the Board of Directors of Oncodesign Precision Medicine

Oncodesign Precision Medicine (OPM) announced the appointment of Christophe Thurieau as an independent director of its Board of Directors. This decision will be submitted to the shareholders' vote at the General Meeting of June 25, 2025.

Christophe Thurieau, current Chief Research Officer at Servier, brings over 35 years of experience in the healthcare field. With a PhD in biochemistry from Pierre and Marie Curie University and training at Harvard Medical School, he worked at Ipsen before joining Servier in 2017.

Philippe Genne, co-founder of OPM, expressed his satisfaction with the arrival of Christophe Thurieau, emphasizing that his expertise will be valuable to the company.